- Home
- NYC vs CLNN Comparison
NYC vs CLNN Comparison
Compare NYC & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- CLNN
- Stock Information
- Founded
- NYC 2013
- CLNN 2012
- Country
- NYC United States
- CLNN United States
- Employees
- NYC N/A
- CLNN N/A
- Industry
- NYC Real Estate
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- CLNN Health Care
- Exchange
- NYC Nasdaq
- CLNN Nasdaq
- Market Cap
- NYC 30.7M
- CLNN 26.1M
- IPO Year
- NYC N/A
- CLNN N/A
- Fundamental
- Price
- NYC $10.55
- CLNN $2.66
- Analyst Decision
- NYC
- CLNN Strong Buy
- Analyst Count
- NYC 0
- CLNN 5
- Target Price
- NYC N/A
- CLNN $40.00
- AVG Volume (30 Days)
- NYC 3.1K
- CLNN 74.4K
- Earning Date
- NYC 05-09-2025
- CLNN 05-07-2025
- Dividend Yield
- NYC N/A
- CLNN N/A
- EPS Growth
- NYC N/A
- CLNN N/A
- EPS
- NYC N/A
- CLNN N/A
- Revenue
- NYC $58,397,000.00
- CLNN $350,000.00
- Revenue This Year
- NYC $8.40
- CLNN N/A
- Revenue Next Year
- NYC $1.62
- CLNN $2,066.67
- P/E Ratio
- NYC N/A
- CLNN N/A
- Revenue Growth
- NYC N/A
- CLNN N/A
- 52 Week Low
- NYC $7.55
- CLNN $2.55
- 52 Week High
- NYC $13.59
- CLNN $9.20
- Technical
- Relative Strength Index (RSI)
- NYC 40.02
- CLNN 37.77
- Support Level
- NYC $10.68
- CLNN $2.91
- Resistance Level
- NYC $11.77
- CLNN $2.90
- Average True Range (ATR)
- NYC 0.64
- CLNN 0.19
- MACD
- NYC -0.09
- CLNN 0.00
- Stochastic Oscillator
- NYC 0.00
- CLNN 18.33
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.